{
  "id": "ms-chronic-management",
  "title": "Multiple Sclerosis - Chronic Management",
  "version": "1.0",
  "icd10": [
    "** G35 (Multiple sclerosis)"
  ],
  "scope": "** Long-term management of established MS including disease-modifying therapy (DMT) monitoring, symptom management optimization, surveillance imaging, preventive care, and special populations (pregnancy planning). Excludes acute MS relapse (see \"MS - Exacerbation\") and initial diagnostic workup (see \"MS - New Diagnosis\"). Primary focus is outpatient management with guidance for ED/hospital presentation of established MS patients.",
  "notes": [],
  "sections": {
    "Laboratory Workup": {
      "Essential/Core Labs": [
        {
          "item": "CBC with differential",
          "rationale": "Baseline monitoring; DMT safety; infection assessment",
          "target": "Normal; ALC varies by DMT (see 1B)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "CMP",
          "rationale": "Metabolic panel; renal/hepatic function for DMT dosing",
          "target": "Normal",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "LFTs (AST, ALT, ALP, bilirubin)",
          "rationale": "DMT hepatotoxicity monitoring (interferons, teriflunomide, S1P modulators)",
          "target": "AST/ALT <3x ULN",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "URGENT"
        },
        {
          "item": "Urinalysis with culture",
          "rationale": "UTI common MS comorbidity; can trigger pseudorelapse",
          "target": "Negative",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "TSH",
          "rationale": "Thyroid dysfunction (interferons, alemtuzumab)",
          "target": "Normal (0.4-4.0 mIU/L)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Vitamin D, 25-hydroxy",
          "rationale": "Deficiency associated with disease activity",
          "target": ">40 ng/mL (target >50)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Extended Workup": [
        {
          "item": "**INTERFERONS (Avonex, Rebif, Betaseron, Plegridy)**"
        },
        {
          "item": "CBC with differential",
          "rationale": "Leukopenia, thrombocytopenia monitoring",
          "target": "WBC >3000, ANC >1500, Plt >100K",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "LFTs",
          "rationale": "Hepatotoxicity",
          "target": "AST/ALT <3x ULN",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "TSH",
          "rationale": "Thyroid dysfunction",
          "target": "Normal",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "**GLATIRAMER ACETATE (Copaxone, Glatopa)**"
        },
        {
          "item": "No routine labs required",
          "rationale": "Minimal systemic toxicity",
          "target": "N/A",
          "ED": "-",
          "HOSP": "-",
          "OPD": "-",
          "ICU": "-"
        },
        {
          "item": "**DIMETHYL/DIROXIMEL FUMARATE (Tecfidera, Vumerity)**"
        },
        {
          "item": "CBC with differential",
          "rationale": "Lymphopenia (PML risk if ALC <500 for >6 months)",
          "target": "ALC >500/uL; discontinue if ALC <500 x6mo",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "LFTs",
          "rationale": "Hepatotoxicity",
          "target": "AST/ALT <3x ULN",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "**TERIFLUNOMIDE (Aubagio)**"
        },
        {
          "item": "CBC with differential",
          "rationale": "Leukopenia",
          "target": "WBC >3000, ANC >1500",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "LFTs",
          "rationale": "Hepatotoxicity (black box warning)",
          "target": "ALT <3x ULN; discontinue if >3x with symptoms",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Blood pressure",
          "rationale": "Hypertension",
          "target": "<140/90 mmHg",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Pregnancy test",
          "rationale": "Teratogenic (Category X)",
          "target": "Negative",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "**FINGOLIMOD (Gilenya)**"
        },
        {
          "item": "CBC with differential",
          "rationale": "Lymphopenia expected (therapeutic effect)",
          "target": "ALC 200-600/uL typical; concern if <200",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "LFTs",
          "rationale": "Hepatotoxicity",
          "target": "AST/ALT <3x ULN",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "VZV IgG",
          "rationale": "Pre-treatment; vaccinate if negative",
          "target": "Positive (immune)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "**SIPONIMOD (Mayzent)**"
        },
        {
          "item": "CBC with differential",
          "rationale": "Lymphopenia",
          "target": "ALC 200-600/uL typical",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "LFTs",
          "rationale": "Hepatotoxicity",
          "target": "AST/ALT <3x ULN",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "CYP2C9 genotype",
          "rationale": "Required before initiation; determines dosing",
          "target": "*1/*3 or *2/*3: 1 mg dose; *3/*3: contraindicated",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "**OZANIMOD (Zeposia) / PONESIMOD (Ponvory)**"
        },
        {
          "item": "CBC with differential",
          "rationale": "Lymphopenia",
          "target": "ALC 200-600/uL typical",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "LFTs",
          "rationale": "Hepatotoxicity",
          "target": "AST/ALT <3x ULN",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "**NATALIZUMAB (Tysabri)**"
        },
        {
          "item": "JCV antibody with index",
          "rationale": "PML risk stratification",
          "target": "Negative preferred; if positive, index <0.9 lower risk",
          "ED": "URGENT",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "URGENT"
        },
        {
          "item": "CBC with differential",
          "rationale": "Infusion reactions; general monitoring",
          "target": "Normal",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "LFTs",
          "rationale": "Hepatotoxicity",
          "target": "AST/ALT <3x ULN",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "**OCRELIZUMAB (Ocrevus) / OFATUMUMAB (Kesimpta) / UBLITUXIMAB (Briumvi)**"
        },
        {
          "item": "Hepatitis B surface antigen, core antibody",
          "rationale": "Reactivation risk",
          "target": "Negative; if positive, HBV DNA and GI/ID consult",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Quantitative immunoglobulins (IgG, IgA, IgM)",
          "rationale": "Hypogammaglobulinemia risk",
          "target": "IgG >400 mg/dL",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "CD19/CD20 B-cell count",
          "rationale": "Therapeutic monitoring",
          "target": "B-cell depletion expected",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "**ALEMTUZUMAB (Lemtrada)**"
        },
        {
          "item": "CBC with platelet count",
          "rationale": "ITP, neutropenia (monthly x 48 months after last dose)",
          "target": "Platelets >100K; report petechiae/bruising",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Serum creatinine, urinalysis",
          "rationale": "Anti-GBM nephropathy (monthly x 48 months)",
          "target": "Creatinine stable; UA negative for RBCs/protein",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "TSH",
          "rationale": "Autoimmune thyroid disease (quarterly x 48 months)",
          "target": "Normal",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "**CLADRIBINE (Mavenclad)**"
        },
        {
          "item": "CBC with differential",
          "rationale": "Lymphopenia (target); timing critical",
          "target": "ALC >800 before year 2; monitoring at months 2 and 6",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "LFTs",
          "rationale": "Hepatotoxicity",
          "target": "AST/ALT <3x ULN",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Rare/Specialized": [
        {
          "item": "JCV PCR (CSF)",
          "rationale": "Suspected PML (focal neuro symptoms on natalizumab/DMF/fingolimod)",
          "target": "Negative (if positive, confirms PML)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Serum natalizumab antibodies",
          "rationale": "Suspected infusion reactions or loss of efficacy",
          "target": "Negative",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "Anti-drug antibodies (interferon)",
          "rationale": "Suspected neutralizing antibodies with breakthrough disease",
          "target": "Negative",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "Serum neurofilament light chain (NfL)",
          "rationale": "Research/emerging; monitor subclinical disease activity",
          "target": "Low/stable (no established threshold)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "Pregnancy test (urine or serum)",
          "rationale": "Before DMT initiation or if pregnancy suspected",
          "target": "Negative before teratogenic DMTs",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ]
    },
    "Imaging & Studies": {
      "Essential/First-line": [
        {
          "item": "MRI brain with and without contrast (MS protocol)",
          "timing": "Annual surveillance; 3-6 months after DMT change",
          "target": "No new/enlarging T2 lesions; no new enhancing lesions (NEDA-3)",
          "contraindications": "GFR <30; gadolinium allergy; pacemaker",
          "ED": "URGENT",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "URGENT"
        },
        {
          "item": "MRI C-spine with and without contrast",
          "timing": "Annual or with new symptoms; baseline if not done",
          "target": "No new cord lesions",
          "contraindications": "GFR <30; gadolinium allergy; pacemaker",
          "ED": "URGENT",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "URGENT"
        },
        {
          "item": "MRI T-spine with and without contrast",
          "timing": "Baseline; repeat if new lower extremity symptoms",
          "target": "No new cord lesions",
          "contraindications": "GFR <30; gadolinium allergy; pacemaker",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "URGENT"
        }
      ],
      "Extended": [
        {
          "item": "MRI brain for PML surveillance (natalizumab, DMF, fingolimod)",
          "timing": "q3-6 months if high JCV risk; q12 months if low risk",
          "target": "No new periventricular or subcortical lesions without enhancement",
          "contraindications": "Standard MRI contraindications",
          "ED": "URGENT",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "URGENT"
        },
        {
          "item": "OCT (optical coherence tomography)",
          "timing": "Annual; baseline; after optic neuritis",
          "target": "Stable RNFL thickness (>5 micron/year loss is pathological)",
          "contraindications": "None",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Visual evoked potentials",
          "timing": "Baseline; suspected subclinical optic nerve involvement",
          "target": "Stable P100 latency",
          "contraindications": "None",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "ECG",
          "timing": "S1P modulators (fingolimod, siponimod) first dose; baseline and annually",
          "target": "Normal sinus rhythm; PR <200 ms; QTc <500 ms",
          "contraindications": "None",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Ophthalmology exam (macular OCT)",
          "timing": "S1P modulators at 3-4 months; then annually",
          "target": "No macular edema",
          "contraindications": "None",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Pulmonary function tests",
          "timing": "If respiratory symptoms; alemtuzumab monitoring",
          "target": "FVC >80% predicted",
          "contraindications": "None",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Rare/Specialized": [
        {
          "item": "PET-CT",
          "timing": "Suspected malignancy (lymphoma risk with immunosuppression)",
          "target": "No FDG-avid lesions",
          "contraindications": "Pregnancy; uncontrolled diabetes",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "Urodynamic studies",
          "timing": "Refractory bladder symptoms",
          "target": "Defines neurogenic bladder type (hyperreflexic vs hyporeflexic)",
          "contraindications": "Active UTI",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "Video swallow study",
          "timing": "Dysphagia or recurrent aspiration",
          "target": "Safe swallow; define texture modifications",
          "contraindications": "None",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Sleep study (polysomnography)",
          "timing": "Severe fatigue; suspected sleep apnea",
          "target": "AHI <5/hour",
          "contraindications": "None",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "DEXA scan",
          "timing": "Long-term steroid exposure; mobility impairment; menopause",
          "target": "T-score >-2.5",
          "contraindications": "None",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ]
    },
    "Treatment": {
      "Acute/Emergent (MS Patient Presenting to ED/Hospital)": [
        {
          "item": "Continue home DMT",
          "route": "Various",
          "indication": "Established MS patient on DMT",
          "dosing": {
            "doseOptions": [
              {
                "text": "Home dose",
                "orderSentence": "Continue home DMT Home dose Home route"
              }
            ],
            "route": "Home route",
            "instructions": "Verify home DMT and continue unless contraindicated; consult neurology for infusion therapies",
            "orderSentence": "Continue home DMT Home dose Home route"
          },
          "contraindications": "Varies by DMT",
          "monitoring": "Per DMT",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Methylprednisolone IV",
          "route": "IV",
          "indication": "Acute MS relapse",
          "dosing": {
            "doseOptions": [
              {
                "text": "1000 mg",
                "orderSentence": "Methylprednisolone IV 1000 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "1000 mg IV daily for 3-5 days; infuse over 1 hour",
            "orderSentence": "Methylprednisolone IV 1000 mg IV"
          },
          "contraindications": "Active infection; uncontrolled diabetes; psychosis",
          "monitoring": "Glucose q6h; BP; mood",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Omeprazole",
          "route": "PO",
          "indication": "GI prophylaxis during steroids",
          "dosing": {
            "doseOptions": [
              {
                "text": "20 mg daily",
                "orderSentence": "Omeprazole 20 mg daily PO"
              },
              {
                "text": "40 mg daily",
                "orderSentence": "Omeprazole 40 mg daily PO"
              }
            ],
            "route": "PO",
            "instructions": "20-40 mg PO daily during steroids",
            "orderSentence": "Omeprazole 20 mg daily PO"
          },
          "contraindications": "PPI allergy",
          "monitoring": "None",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Insulin sliding scale",
          "route": "SC",
          "indication": "Steroid-induced hyperglycemia",
          "dosing": {
            "doseOptions": [
              {
                "text": "Per protocol",
                "orderSentence": "Insulin sliding scale Per protocol SC"
              }
            ],
            "route": "SC",
            "instructions": "Per protocol if glucose >180 mg/dL",
            "orderSentence": "Insulin sliding scale Per protocol SC"
          },
          "contraindications": "Hypoglycemia risk",
          "monitoring": "Glucose q6h",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        }
      ],
      "Symptomatic Treatments - Fatigue": [
        {
          "item": "Amantadine",
          "route": "PO",
          "indication": "MS-related fatigue (first-line)",
          "dosing": {
            "doseOptions": [
              {
                "text": "100 mg qAM",
                "orderSentence": "Amantadine 100 mg qAM PO"
              },
              {
                "text": "100 mg BID",
                "orderSentence": "Amantadine 100 mg BID PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 100 mg every morning; may add 100 mg early afternoon (before 2 PM to avoid insomnia); max 200 mg/day",
            "orderSentence": "Amantadine 100 mg qAM PO"
          },
          "contraindications": "Renal impairment (adjust dose CrCl <50); seizure history; uncontrolled glaucoma",
          "monitoring": "Livedo reticularis; ankle edema; hallucinations; insomnia",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Modafinil",
          "route": "PO",
          "indication": "MS-related fatigue (second-line); Schedule IV",
          "dosing": {
            "doseOptions": [
              {
                "text": "100 mg qAM",
                "orderSentence": "Modafinil 100 mg qAM PO"
              },
              {
                "text": "200 mg qAM",
                "orderSentence": "Modafinil 200 mg qAM PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 100 mg every morning; may increase to 200 mg; max 200 mg daily; take early AM",
            "orderSentence": "Modafinil 100 mg qAM PO"
          },
          "contraindications": "Cardiac arrhythmia; left ventricular hypertrophy; mitral valve prolapse",
          "monitoring": "BP; HR; may reduce hormonal contraception efficacy",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Armodafinil",
          "route": "PO",
          "indication": "MS-related fatigue; longer half-life; Schedule IV",
          "dosing": {
            "doseOptions": [
              {
                "text": "150 mg qAM",
                "orderSentence": "Armodafinil 150 mg qAM PO"
              }
            ],
            "route": "PO",
            "instructions": "150 mg every morning; longer duration than modafinil",
            "orderSentence": "Armodafinil 150 mg qAM PO"
          },
          "contraindications": "Same as modafinil",
          "monitoring": "Same as modafinil",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Methylphenidate",
          "route": "PO",
          "indication": "Refractory fatigue; Schedule II",
          "dosing": {
            "doseOptions": [
              {
                "text": "5 mg BID",
                "orderSentence": "Methylphenidate 5 mg BID PO"
              },
              {
                "text": "10 mg BID",
                "orderSentence": "Methylphenidate 10 mg BID PO"
              },
              {
                "text": "20 mg BID",
                "orderSentence": "Methylphenidate 20 mg BID PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 5 mg morning and noon; titrate by 5-10 mg/week; max 60 mg/day; avoid afternoon dosing",
            "orderSentence": "Methylphenidate 5 mg BID PO"
          },
          "contraindications": "Marked anxiety; glaucoma; motor tics; MAOIs; severe hypertension",
          "monitoring": "BP; HR; appetite; mood; growth (rare in adults)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Second-line/Refractory Acute Treatments": [
        {
          "item": "Plasmapheresis (PLEX)",
          "route": "—",
          "indication": "Steroid-refractory acute relapse",
          "dosing": {
            "doseOptions": [
              {
                "text": "5-7 exchanges",
                "orderSentence": "Plasmapheresis (PLEX) 5-7 exchanges —"
              }
            ],
            "route": "—",
            "instructions": "5-7 exchanges over 10-14 days; 1-1.5 plasma volumes per exchange",
            "orderSentence": "Plasmapheresis (PLEX) 5-7 exchanges —"
          },
          "contraindications": "Hemodynamic instability; sepsis; central line contraindication",
          "monitoring": "BP; electrolytes; coagulation; fibrinogen; line infection",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "-",
          "ICU": "URGENT"
        },
        {
          "item": "IVIG",
          "route": "IV",
          "indication": "Steroid-refractory relapse (alternative to PLEX)",
          "dosing": {
            "doseOptions": [
              {
                "text": "0.4 g/kg/day",
                "orderSentence": "IVIG 0.4 g/kg/day IV"
              }
            ],
            "route": "IV",
            "instructions": "0.4 g/kg/day x 5 days (total 2 g/kg)",
            "orderSentence": "IVIG 0.4 g/kg/day IV"
          },
          "contraindications": "IgA deficiency; renal failure; thrombosis history",
          "monitoring": "Renal function; headache; aseptic meningitis; thrombosis",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "-",
          "ICU": "URGENT"
        }
      ],
      "Disease-Modifying Therapies - Monitoring Protocols": [
        {
          "item": "**INJECTABLE DMTs**"
        },
        {
          "item": "Interferon beta (any formulation)",
          "route": "IM/SC",
          "indication": "RRMS; established patient on therapy",
          "dosing": {
            "doseOptions": [
              {
                "text": "Per product labeling",
                "orderSentence": "Interferon beta (any formulation) Per product labeling IM/SC"
              }
            ],
            "route": "IM/SC",
            "instructions": "Continue established regimen",
            "orderSentence": "Interferon beta (any formulation) Per product labeling IM/SC"
          },
          "pretreatment": "CBC, LFTs, TSH at baseline",
          "contraindications": "Decompensated liver disease; depression (relative)",
          "monitoring": "CBC, LFTs q3-6 months; TSH annually; depression screening",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Glatiramer acetate (any formulation)",
          "route": "SC",
          "indication": "RRMS; established patient",
          "dosing": {
            "doseOptions": [
              {
                "text": "20 mg daily or 40 mg TIW",
                "orderSentence": "Glatiramer acetate (any formulation) 20 mg daily or 40 mg TIW SC"
              }
            ],
            "route": "SC",
            "instructions": "Continue established regimen",
            "orderSentence": "Glatiramer acetate (any formulation) 20 mg daily or 40 mg TIW SC"
          },
          "pretreatment": "None required",
          "contraindications": "Hypersensitivity",
          "monitoring": "Injection site reactions; post-injection reaction (self-limited)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "**ORAL DMTs - MODERATE EFFICACY**"
        },
        {
          "item": "Dimethyl fumarate (Tecfidera)",
          "route": "PO",
          "indication": "RRMS; established patient",
          "dosing": {
            "doseOptions": [
              {
                "text": "240 mg BID",
                "orderSentence": "Dimethyl fumarate (Tecfidera) 240 mg BID PO"
              }
            ],
            "route": "PO",
            "instructions": "Continue 240 mg BID with food",
            "orderSentence": "Dimethyl fumarate (Tecfidera) 240 mg BID PO"
          },
          "pretreatment": "CBC, LFTs",
          "contraindications": "ALC <500 for >6 months (discontinue); PML risk",
          "monitoring": "CBC q6 months; LFTs periodically; MRI surveillance for PML",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Diroximel fumarate (Vumerity)",
          "route": "PO",
          "indication": "RRMS; less GI side effects than Tecfidera",
          "dosing": {
            "doseOptions": [
              {
                "text": "462 mg BID",
                "orderSentence": "Diroximel fumarate (Vumerity) 462 mg BID PO"
              }
            ],
            "route": "PO",
            "instructions": "Continue 462 mg BID with food",
            "orderSentence": "Diroximel fumarate (Vumerity) 462 mg BID PO"
          },
          "pretreatment": "CBC, LFTs",
          "contraindications": "ALC <500 for >6 months (discontinue); PML risk",
          "monitoring": "CBC q6 months; LFTs periodically; MRI surveillance for PML",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Teriflunomide (Aubagio)",
          "route": "PO",
          "indication": "RRMS; established patient",
          "dosing": {
            "doseOptions": [
              {
                "text": "7 mg or 14 mg daily",
                "orderSentence": "Teriflunomide (Aubagio) 7 mg or 14 mg daily PO"
              }
            ],
            "route": "PO",
            "instructions": "Continue established dose",
            "orderSentence": "Teriflunomide (Aubagio) 7 mg or 14 mg daily PO"
          },
          "pretreatment": "LFTs monthly x 6 months; TB test; BP; pregnancy test",
          "contraindications": "Pregnancy (Category X); severe hepatic impairment",
          "monitoring": "LFTs monthly x 6 months, then periodically; BP; pregnancy test PRN",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "**ORAL DMTs - S1P MODULATORS (HIGH EFFICACY)**"
        },
        {
          "item": "Fingolimod (Gilenya)",
          "route": "PO",
          "indication": "RRMS; established patient",
          "dosing": {
            "doseOptions": [
              {
                "text": "0.5 mg daily",
                "orderSentence": "Fingolimod (Gilenya) 0.5 mg daily PO"
              }
            ],
            "route": "PO",
            "instructions": "Continue 0.5 mg daily",
            "orderSentence": "Fingolimod (Gilenya) 0.5 mg daily PO"
          },
          "pretreatment": "First-dose observation completed; VZV immune; macular OCT; ECG",
          "contraindications": "Cardiac conduction issues; recent MI/stroke; macular edema",
          "monitoring": "Macular OCT annually; CBC q6-12 months; LFTs annually; MRI for PML surveillance",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Siponimod (Mayzent)",
          "route": "PO",
          "indication": "SPMS or RRMS; established patient",
          "dosing": {
            "doseOptions": [
              {
                "text": "1 mg or 2 mg daily (per CYP2C9)",
                "orderSentence": "Siponimod (Mayzent) 1 mg or 2 mg daily (per CYP2C9) PO"
              }
            ],
            "route": "PO",
            "instructions": "Continue established dose per genotype",
            "orderSentence": "Siponimod (Mayzent) 1 mg or 2 mg daily (per CYP2C9) PO"
          },
          "pretreatment": "CYP2C9 genotype; first-dose observation; macular OCT",
          "contraindications": "CYP2C9 *3/*3; cardiac conduction issues; macular edema",
          "monitoring": "Macular OCT annually; CBC q6-12 months; LFTs annually",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Ozanimod (Zeposia)",
          "route": "PO",
          "indication": "RRMS; established patient",
          "dosing": {
            "doseOptions": [
              {
                "text": "0.92 mg daily",
                "orderSentence": "Ozanimod (Zeposia) 0.92 mg daily PO"
              }
            ],
            "route": "PO",
            "instructions": "Continue 0.92 mg daily",
            "orderSentence": "Ozanimod (Zeposia) 0.92 mg daily PO"
          },
          "pretreatment": "Macular OCT; ECG (no first-dose observation required)",
          "contraindications": "Cardiac conduction issues; recent MI/stroke; MAOIs",
          "monitoring": "Macular OCT at 3-4 months then annually; CBC; LFTs",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Ponesimod (Ponvory)",
          "route": "PO",
          "indication": "RRMS; established patient",
          "dosing": {
            "doseOptions": [
              {
                "text": "20 mg daily",
                "orderSentence": "Ponesimod (Ponvory) 20 mg daily PO"
              }
            ],
            "route": "PO",
            "instructions": "Continue 20 mg daily",
            "orderSentence": "Ponesimod (Ponvory) 20 mg daily PO"
          },
          "pretreatment": "Macular OCT; ECG (no first-dose observation required)",
          "contraindications": "Cardiac conduction issues; recent MI/stroke",
          "monitoring": "Macular OCT at 3-4 months then annually; CBC; LFTs",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "**ORAL DMTs - HIGH EFFICACY OTHER**"
        },
        {
          "item": "Cladribine (Mavenclad)",
          "route": "PO",
          "indication": "RRMS/SPMS; induction therapy",
          "dosing": {
            "doseOptions": [
              {
                "text": "1.75 mg/kg/year x 2 years",
                "orderSentence": "Cladribine (Mavenclad) 1.75 mg/kg/year x 2 years PO"
              }
            ],
            "route": "PO",
            "instructions": "Year 1 and Year 2 only; no treatment years 3-4",
            "orderSentence": "Cladribine (Mavenclad) 1.75 mg/kg/year x 2 years PO"
          },
          "pretreatment": "ALC >800 before each year; LFTs; HIV; Hep B/C",
          "contraindications": "Active infection; HIV; malignancy; pregnancy",
          "monitoring": "CBC at months 2 and 6 each treatment year; malignancy screening",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "**INFUSION DMTs - HIGH EFFICACY**"
        },
        {
          "item": "Natalizumab (Tysabri)",
          "route": "IV",
          "indication": "RRMS; established patient",
          "dosing": {
            "doseOptions": [
              {
                "text": "300 mg q4 weeks or extended q6 weeks",
                "orderSentence": "Natalizumab (Tysabri) 300 mg q4 weeks or extended q6 weeks IV"
              }
            ],
            "route": "IV",
            "instructions": "Standard interval q4 weeks; extended interval dosing (EID) q6 weeks if stable and JCV negative",
            "orderSentence": "Natalizumab (Tysabri) 300 mg q4 weeks or extended q6 weeks IV"
          },
          "pretreatment": "JCV antibody q6 months; REMS enrollment",
          "contraindications": "JCV+ with index >1.5 and prior immunosuppression (high PML risk)",
          "monitoring": "JCV q6 months; MRI q3-6 months (high risk) or q6-12 months (low risk) for PML surveillance",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Ocrelizumab (Ocrevus)",
          "route": "IV",
          "indication": "RRMS/PPMS; established patient",
          "dosing": {
            "doseOptions": [
              {
                "text": "600 mg q6 months",
                "orderSentence": "Ocrelizumab (Ocrevus) 600 mg q6 months IV"
              }
            ],
            "route": "IV",
            "instructions": "600 mg IV every 6 months; premedicate",
            "orderSentence": "Ocrelizumab (Ocrevus) 600 mg q6 months IV"
          },
          "pretreatment": "Hepatitis B screening; TB test; immunoglobulins",
          "contraindications": "Active Hepatitis B; active infection",
          "monitoring": "IgG annually; infection monitoring; infusion reactions",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Ofatumumab (Kesimpta)",
          "route": "SC",
          "indication": "RRMS; established patient",
          "dosing": {
            "doseOptions": [
              {
                "text": "20 mg monthly",
                "orderSentence": "Ofatumumab (Kesimpta) 20 mg monthly SC"
              }
            ],
            "route": "SC",
            "instructions": "20 mg SC monthly; self-administered at home",
            "orderSentence": "Ofatumumab (Kesimpta) 20 mg monthly SC"
          },
          "pretreatment": "Hepatitis B screening; TB test; immunoglobulins",
          "contraindications": "Active Hepatitis B; active infection",
          "monitoring": "IgG annually; infection monitoring",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Ublituximab (Briumvi)",
          "route": "IV",
          "indication": "RRMS; established patient",
          "dosing": {
            "doseOptions": [
              {
                "text": "450 mg q6 months",
                "orderSentence": "Ublituximab (Briumvi) 450 mg q6 months IV"
              }
            ],
            "route": "IV",
            "instructions": "450 mg IV every 24 weeks (after initial doses); 1-hour infusion",
            "orderSentence": "Ublituximab (Briumvi) 450 mg q6 months IV"
          },
          "pretreatment": "Hepatitis B screening; TB test; immunoglobulins",
          "contraindications": "Active Hepatitis B; active infection",
          "monitoring": "IgG annually; infection monitoring; infusion reactions",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Alemtuzumab (Lemtrada)",
          "route": "IV",
          "indication": "RRMS; established patient post-induction",
          "dosing": {
            "doseOptions": [
              {
                "text": "No further dosing unless rebound",
                "orderSentence": "Alemtuzumab (Lemtrada) No further dosing unless rebound IV"
              }
            ],
            "route": "IV",
            "instructions": "Monitoring continues 48 months after last infusion even without additional dosing",
            "orderSentence": "Alemtuzumab (Lemtrada) No further dosing unless rebound IV"
          },
          "pretreatment": "REMS enrollment; extensive baseline labs",
          "contraindications": "Active infection; ongoing autoimmune disease",
          "monitoring": "CBC monthly x 48 months; TSH q3 months x 48 months; creatinine/UA monthly x 48 months",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ]
    },
    "Other Recommendations": {
      "Referrals & Consults": [
        {
          "item": "MS specialist/Neuroimmunology for annual comprehensive review and DMT optimization",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Neuro-ophthalmology for visual complaints, OCT monitoring, or suspected optic neuritis",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Physical therapy for gait training, balance exercises, and fall prevention given progressive mobility decline",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Occupational therapy for ADL assessment, energy conservation strategies, and adaptive equipment",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Speech therapy for dysphagia evaluation given brainstem involvement or swallowing concerns",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "URGENT"
        },
        {
          "item": "Neuropsychology for formal cognitive testing if subjective or objective cognitive decline",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Cognitive rehabilitation (speech therapy or neuropsychology) for documented cognitive impairment",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Urology for refractory bladder symptoms, recurrent UTIs, or urodynamic testing consideration",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Psychiatry for depression, anxiety, or adjustment disorders not responding to first-line treatment",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Pain management for refractory neuropathic pain not responding to multiple first-line agents",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Physiatry/Rehabilitation medicine for comprehensive rehabilitation planning and spasticity management",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Social work for disability planning, insurance navigation, and community resource connection",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Genetic counseling if considering pregnancy with strong family history or known genetic mutations",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "High-risk OB for pregnancy planning discussion in women on DMTs",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Infusion center for DMT administration and monitoring",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Palliative care for advanced MS with significant symptom burden or goals of care discussions",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Patient Instructions": [
        {
          "item": "Return immediately if rapid vision loss, new weakness, numbness, or difficulty walking develops (may indicate relapse requiring steroids)",
          "ED": "ROUTINE",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Report fever or signs of infection promptly as immunomodulatory DMTs increase infection risk",
          "ED": "ROUTINE",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Continue DMT as prescribed unless instructed otherwise by neurology - do not stop without discussing",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Avoid live vaccines while on immunosuppressive DMTs (fingolimod, siponimod, cladribine, anti-CD20 therapies, alemtuzumab)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Heat may temporarily worsen symptoms (Uhthoff phenomenon) - use cooling strategies; this is NOT a new relapse",
          "ED": "ROUTINE",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Maintain symptom diary noting new symptoms, fatigue levels, and bladder/bowel patterns",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Do not stop baclofen or tizanidine abruptly - taper under medical supervision to avoid withdrawal",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Report any skin changes, new moles, or suspicious lesions given increased malignancy risk with some DMTs",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE"
        },
        {
          "item": "Women of childbearing potential: discuss pregnancy plans with MS specialist before conception given DMT-specific washout requirements",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Report unusual fatigue, shortness of breath, chest pain, or palpitations if on S1P modulators (cardiac effects)",
          "ED": "ROUTINE",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "If on natalizumab: report any new neurological symptoms, especially if subtle (confusion, personality change, clumsiness) as may indicate PML",
          "ED": "URGENT",
          "HOSP": "URGENT",
          "OPD": "ROUTINE"
        },
        {
          "item": "Take dalfampridine exactly 12 hours apart and never exceed 2 doses per day (seizure risk)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        }
      ],
      "Lifestyle & Prevention": [
        {
          "item": "Smoking cessation - smoking accelerates MS progression, increases relapse rate, and worsens disability",
          "ED": "ROUTINE",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Vitamin D supplementation 2000-5000 IU daily to maintain serum 25-OH vitamin D >40 ng/mL (target >50 ng/mL)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Regular aerobic exercise 150 minutes per week as tolerated - improves fatigue, mood, mobility, and may slow progression",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Aquatic therapy/swimming - allows exercise with built-in cooling and reduced fall risk",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Resistance training 2-3 times weekly for strength maintenance and bone health",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE"
        },
        {
          "item": "Stress management techniques as stress may trigger pseudorelapses and worsen fatigue",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Sleep hygiene - ensure 7-8 hours nightly; address sleep disorders contributing to fatigue",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Avoid excessive heat exposure (hot tubs, saunas, exercising in heat) - use cooling vests for outdoor activities",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Fall prevention: remove loose rugs, ensure adequate lighting, use assistive devices (cane, walker) as needed",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Complete recommended vaccinations before starting immunosuppressive DMTs - inactivated vaccines safe on most DMTs",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Annual influenza vaccine (inactivated) and COVID-19 vaccines per current guidelines (timing around infusions for anti-CD20)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Limit alcohol intake as it can worsen balance, cognitive symptoms, and interact with medications",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE"
        },
        {
          "item": "Mediterranean diet pattern may have anti-inflammatory benefits based on observational data",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE"
        },
        {
          "item": "DEXA scan for bone density monitoring if prolonged steroid exposure, immobility, or menopause",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE"
        }
      ]
    }
  },
  "differential": [
    {
      "diagnosis": "MS relapse vs pseudorelapse",
      "features": "True relapse: new neuroinflammation; Pseudorelapse: symptom worsening from infection, heat, stress without new inflammation",
      "tests": "MRI with contrast (new enhancing lesions = true relapse); infection workup (UTI, URI)"
    },
    {
      "diagnosis": "Progressive multifocal leukoencephalopathy (PML)",
      "features": "Subacute cognitive/behavioral change, visual, motor symptoms; on natalizumab, DMF, fingolimod",
      "tests": "MRI (subcortical non-enhancing lesions); CSF JCV PCR"
    },
    {
      "diagnosis": "CNS infection",
      "features": "Fever, meningeal signs, rapid deterioration; immunosuppressed",
      "tests": "Lumbar puncture; blood cultures; imaging"
    },
    {
      "diagnosis": "Comorbid stroke/TIA",
      "features": "Sudden onset; vascular risk factors; non-MS territory",
      "tests": "MRI DWI; vascular imaging"
    },
    {
      "diagnosis": "Medication side effect",
      "features": "Temporal relationship to new medication or dose change",
      "tests": "Medication review; trial discontinuation"
    },
    {
      "diagnosis": "Functional neurological disorder",
      "features": "Inconsistent exam; non-anatomical patterns; psychiatric comorbidity",
      "tests": "Clinical assessment; normal MRI"
    },
    {
      "diagnosis": "B12 deficiency myelopathy",
      "features": "Progressive; dorsal column signs; may coexist with MS",
      "tests": "B12, MMA, homocysteine"
    },
    {
      "diagnosis": "Secondary malignancy",
      "features": "Progressive; atypical pattern; on immunosuppressive DMT",
      "tests": "PET-CT; biopsy if indicated"
    }
  ],
  "evidence": [
    {
      "recommendation": "Annual MRI surveillance for subclinical disease activity",
      "evidenceLevel": "Class II, Level B",
      "source": "[Wattjes MP et al. Lancet Neurol 2021 (MAGNIMS-CMSC-NAIMS)](https://pubmed.ncbi.nlm.nih.gov/34139157/)"
    },
    {
      "recommendation": "NEDA (No Evidence of Disease Activity) as treatment target",
      "evidenceLevel": "Class II, Level B",
      "source": "[Giovannoni G et al. Neurology 2017](https://pubmed.ncbi.nlm.nih.gov/28698253/)"
    },
    {
      "recommendation": "JCV antibody monitoring for PML risk stratification",
      "evidenceLevel": "Class I, Level A",
      "source": "[Bloomgren G et al. NEJM 2012](https://pubmed.ncbi.nlm.nih.gov/22316447/)"
    },
    {
      "recommendation": "Extended interval dosing of natalizumab reduces PML risk",
      "evidenceLevel": "Class II, Level B",
      "source": "[Zhovtis Ryerson L et al. Ann Neurol 2019](https://pubmed.ncbi.nlm.nih.gov/30938869/)"
    },
    {
      "recommendation": "Anti-CD20 therapies effective in RRMS and PPMS",
      "evidenceLevel": "Class I, Level A",
      "source": "[Hauser SL et al. NEJM 2017 (OPERA)](https://pubmed.ncbi.nlm.nih.gov/28002679/)"
    },
    {
      "recommendation": "Vitamin D supplementation reduces relapse rate",
      "evidenceLevel": "Class I, Level B",
      "source": "[Hupperts R et al. Neurology 2019 (SOLAR)](https://pubmed.ncbi.nlm.nih.gov/31594857/)"
    },
    {
      "recommendation": "Dalfampridine improves walking speed",
      "evidenceLevel": "Class I, Level A",
      "source": "[Goodman AD et al. Lancet 2009](https://pubmed.ncbi.nlm.nih.gov/19249634/)"
    },
    {
      "recommendation": "Exercise improves fatigue and quality of life",
      "evidenceLevel": "Class I, Level B",
      "source": "[Heine M et al. Cochrane 2015](https://pubmed.ncbi.nlm.nih.gov/26358158/)"
    },
    {
      "recommendation": "Smoking cessation slows disability progression",
      "evidenceLevel": "Class II, Level B",
      "source": "[Hedstrom AK et al. Brain 2013](https://pubmed.ncbi.nlm.nih.gov/23365092/)"
    },
    {
      "recommendation": "Cognitive rehabilitation improves cognitive outcomes",
      "evidenceLevel": "Class II, Level B",
      "source": "[Chiaravalloti ND et al. Neurology 2013](https://pubmed.ncbi.nlm.nih.gov/23091072/)"
    },
    {
      "recommendation": "S1P modulators: macular edema and cardiac monitoring required",
      "evidenceLevel": "Class I, Level A",
      "source": "[FDA label; Cohen JA et al. NEJM 2010 (fingolimod)](https://pubmed.ncbi.nlm.nih.gov/20089954/)"
    },
    {
      "recommendation": "Alemtuzumab: secondary autoimmunity monitoring for 48 months",
      "evidenceLevel": "Class I, Level A",
      "source": "[CAMMS223 investigators NEJM 2008](https://pubmed.ncbi.nlm.nih.gov/18946064/)"
    },
    {
      "recommendation": "Pregnancy planning with DMT washout periods",
      "evidenceLevel": "Class III, Level B",
      "source": "[Bove R et al. Nat Rev Neurol 2014](https://pubmed.ncbi.nlm.nih.gov/24614515/)"
    },
    {
      "recommendation": "Vaccinations before immunosuppressive DMTs",
      "evidenceLevel": "Expert consensus",
      "source": "[Farez MF et al. Neurology 2019 (AAN guidelines)](https://pubmed.ncbi.nlm.nih.gov/30366971/)"
    }
  ],
  "monitoring": [
    {
      "item": "**CLINICAL**"
    },
    {
      "item": "Neurologic examination (EDSS)",
      "frequency": "Every visit; minimum annually",
      "action": "If worsening: MRI, DMT optimization discussion",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Relapse frequency",
      "frequency": "Continuous; review at each visit",
      "action": "Any relapse triggers MRI and DMT reassessment",
      "ED": "-",
      "HOSP": "-",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Walking speed (T25FW)",
      "frequency": "Annually",
      "action": "If worsening: PT referral, dalfampridine consideration",
      "ED": "-",
      "HOSP": "-",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Cognition (SDMT or MoCA)",
      "frequency": "Annually",
      "action": "Cognitive rehab referral; medication review",
      "ED": "-",
      "HOSP": "-",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Depression screening (PHQ-9)",
      "frequency": "Annually; more often if symptoms",
      "action": "Antidepressant; psychiatry referral",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Fatigue (MFIS or FSS)",
      "frequency": "Each visit",
      "action": "Fatigue management optimization",
      "ED": "-",
      "HOSP": "-",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "**IMAGING**"
    },
    {
      "item": "MRI brain with contrast",
      "frequency": "Annually; 3-6 months after DMT switch",
      "action": "New activity: DMT escalation discussion",
      "ED": "URGENT",
      "HOSP": "URGENT",
      "OPD": "ROUTINE",
      "ICU": "URGENT"
    },
    {
      "item": "MRI spine",
      "frequency": "Annually or with new symptoms",
      "action": "New lesions: DMT reassessment",
      "ED": "URGENT",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Macular OCT",
      "frequency": "Baseline; 3-4 months on S1P modulators; then annually",
      "action": "Macular edema: discontinue S1P modulator; ophthalmology",
      "ED": "-",
      "HOSP": "-",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "**LABORATORY**"
    },
    {
      "item": "CBC with differential",
      "frequency": "q6 months on lymphocyte-depleting DMTs; annually others",
      "action": "Adjust or discontinue DMT per protocol",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "LFTs",
      "frequency": "Per DMT schedule; more frequent early on",
      "action": "Hold DMT if >3x; resume if resolves",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "JCV antibody with index",
      "frequency": "q6 months on natalizumab",
      "action": "Rising index: risk counseling; consider DMT switch",
      "ED": "URGENT",
      "HOSP": "URGENT",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Immunoglobulins (IgG)",
      "frequency": "Annually on anti-CD20 therapies",
      "action": "If low: infection precautions; consider IVIG replacement",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Vitamin D, 25-OH",
      "frequency": "Annually",
      "action": "Increase supplementation if low",
      "ED": "-",
      "HOSP": "-",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "**ALEMTUZUMAB-SPECIFIC (48 months after last infusion)**"
    },
    {
      "item": "CBC with platelets",
      "frequency": "Monthly x 48 months",
      "action": "If low: hold; hematology consult for ITP",
      "ED": "STAT",
      "HOSP": "STAT",
      "OPD": "ROUTINE",
      "ICU": "STAT"
    },
    {
      "item": "TSH",
      "frequency": "q3 months x 48 months",
      "action": "If abnormal: endocrine consult",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Serum creatinine + UA",
      "frequency": "Monthly x 48 months",
      "action": "If abnormal: nephrology consult for anti-GBM disease",
      "ED": "STAT",
      "HOSP": "STAT",
      "OPD": "ROUTINE",
      "ICU": "STAT"
    }
  ],
  "disposition": [
    {
      "disposition": "**Discharge home**",
      "criteria": "Mild symptom worsening attributable to pseudorelapse (infection treated, heat exposure resolved); stable neurologic exam; able to care for self or adequate caregiver support; reliable follow-up"
    },
    {
      "disposition": "**Admit to floor**",
      "criteria": "Moderate-severe acute relapse requiring IV steroids; functional decline preventing safe discharge; diagnostic workup for suspected PML or CNS infection; severe medication side effect requiring monitoring"
    },
    {
      "disposition": "**Admit to ICU**",
      "criteria": "Severe myelitis with respiratory compromise (NIF declining toward -20 cm H2O); brainstem involvement with airway risk; severe infusion reaction; suspected PML with rapid deterioration"
    },
    {
      "disposition": "**Transfer to higher level**",
      "criteria": "PLEX needed but unavailable; MS specialist not available for complex decision-making (PML management, severe breakthrough); MRI unavailable for urgent imaging"
    },
    {
      "disposition": "**Outpatient follow-up**",
      "criteria": "Every 3-6 months for stable patients; q1-3 months during DMT transition or active disease; annually minimum for established stable patients"
    }
  ]
}